Media coverage about Neothetics (NASDAQ:NEOT) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neothetics earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.9061993813635 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Separately, ValuEngine upgraded Neothetics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 17th.

Neothetics (NEOT) opened at $1.47 on Friday. Neothetics has a 12 month low of $0.30 and a 12 month high of $2.63.

Neothetics (NASDAQ:NEOT) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter.

COPYRIGHT VIOLATION NOTICE: “Neothetics (NEOT) Earns Coverage Optimism Rating of 0.08” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at

About Neothetics

Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

Insider Buying and Selling by Quarter for Neothetics (NASDAQ:NEOT)

Receive News & Ratings for Neothetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.